-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Compound Y-1
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2379438-80-7.gif)
| Category | Influenza Virus |
| CAS | 2379438-80-7 |
| Description | Compound Y-1 is a neuraminidase inhibitor with IC50 of 0.21 μM. Compound Y-1 exhibits activity against H1N1 influenza virus. |
Product Information
| Synonyms | Neuraminidase-IN-1; Y-1 |
| IUPAC Name | 3,5-dihydroxy-N-[(E)-(4-hydroxy-3-nitrophenyl)methylideneamino]benzamide |
| Molecular Weight | 317.25 |
| Molecular Formula | C14H11N3O6 |
| Canonical SMILES | C1=CC(=C(C=C1C=NNC(=O)C2=CC(=CC(=C2)O)O)[N+](=O)[O-])O |
| InChI | InChI=1S/C14H11N3O6/c18-10-4-9(5-11(19)6-10)14(21)16-15-7-8-1-2-13(20)12(3-8)17(22)23/h1-7,18-20H,(H,16,21)/b15-7+ |
| InChIKey | MCGROFKAAXXTBN-VIZOYTHASA-N |
| Purity | 99.22% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 456 |
| Exact Mass | 317.06478508 |
| In Vitro | Neuraminidase-IN-1 has good inhibitory effect on the A/WSN/33H1N1 virus strains, with low toxicity and good druggability. |
| Target | IC50: 0.21 μM (neuraminidase) |
| XLogP3-AA | 2.2 |
